New Price Helps Secure Funding For Rubraca In England
Clovis's PARP Inhibitor Will Be Available Through The Cancer Drugs Fund
Executive Summary
Clovis Oncology’s ovarian cancer treatment Rubraca is the latest PARP inhibitor to get the all-clear from the health technology assessment body, NICE.